Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
January 2018
in “Journal of Investigative Dermatology Symposium Proceedings”
TLDR Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
The document reviews the use of tofacitinib, a Janus kinase inhibitor, for treating severe alopecia areata (AA) in adults and adolescents. In an open-label clinical trial involving 66 patients with severe AA, alopecia totalis (AT), or alopecia universalis (AU), tofacitinib administered at 5 mg twice daily for 3 months resulted in a median improvement in the Severity of Alopecia Tool (SALT) score of 21%. About 64% of patients experienced some hair regrowth, and 32% achieved an improvement in SALT score of greater than 50%. However, all 20 patients who were followed up experienced disease relapse within a median of 8.5 weeks after stopping treatment. A retrospective cohort study of 90 adults showed that 77% of potential responders (those with AT or AU of less than 10 years duration or AA) achieved some hair regrowth, with 58% achieving over 50% improvement and 20% achieving full regrowth. In adolescents, a study of 13 patients treated with tofacitinib for 2-16 months resulted in a 93% median improvement in SALT score, with 9 patients experiencing hair regrowth. Adverse events in these studies were generally mild and included infections and headaches. The document concludes that targeted therapy for severe AA is within reach, with tofacitinib showing promise in both adults and adolescents.
View this study on jidsponline.org →
Cited in this study
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
Related
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.